Summary & Overview
CPT 0469U: IriSight CNV Whole Genome Fetal Analysis
CPT code 0469U designates the IriSight™ CNV Analysis, a proprietary whole genome sequencing–based laboratory test from Variantyx Inc. used to detect fetal chromosomal abnormalities, including copy number variants and structural changes, with integrated parental comparison and assessment for maternal cell contamination. As a PLA code, 0469U identifies a single manufacturer-specific assay and matters nationally because it defines a unique billing pathway for an advanced prenatal genetic diagnostic service that may impact coverage policies and payment practices across payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and laboratory setting for the test, followed by benchmarks and policy context relevant to proprietary genetic assays. The publication summarizes coding specifics, payer coverage patterns, clinical indications and service utilization considerations, and where available, reimbursement and billing nuances tied to PLA coding. The content is intended to inform clinicians, laboratory administrators, and policy analysts about the code’s scope, typical use-case, and implications for billing and coverage at a national level.
Billing Code Overview
CPT code 0469U is a Proprietary Laboratory Analyses (PLA) code that applies solely to the IriSight™ CNV Analysis from Variantyx Inc. This test performs whole genome sequence analysis on fetal samples to detect chromosomal abnormalities, including copy number variants and other structural changes. The diagnostic report integrates sequencing findings and, when available, compares fetal results against maternal and paternal samples to assist in variant identification and categorization while accounting for potential maternal cell contamination.
-
Service Type: Genetic diagnostic testing using whole genome sequencing and specialized bioinformatic analysis for fetal chromosomal abnormality detection
-
Typical Site of Service: Clinical or commercial molecular diagnostic laboratory; specimens originate from prenatal/fetal sampling (lab-performed testing)
Clinical & Coding Specifications
Clinical Context
A pregnant patient undergoes genetic evaluation after abnormal prenatal screening or ultrasound findings suggestive of chromosomal imbalance (for example, fetal structural abnormalities, growth restriction, or increased risk on noninvasive prenatal testing). A maternal-fetal medicine specialist or obstetrician orders the IriSight™ CNV Analysis (0469U) when whole genome sequencing-based copy number variant (CNV) analysis on a fetal sample (amniotic fluid, chorionic villus sample, or fetal blood) is needed to detect deletions, duplications, aneuploidies, and other structural chromosomal abnormalities. The clinical workflow includes sample collection at the outpatient or hospital ambulatory setting; specimen shipment to Variantyx Inc.; laboratory receipt and whole genome sequencing with bioinformatic CNV calling; integration of fetal results with available parental samples to determine inheritance and to assess for maternal cell contamination; generation of a diagnostic report summarizing clinically significant CNVs and interpretation; and transmission of results to the ordering clinician for counseling and management decisions. Typical sites of service are outpatient clinics, maternal-fetal medicine centers, hospital ambulatory surgical units, and specialized prenatal diagnostic laboratories. Indications include suspected chromosomal disorders, abnormal ultrasound findings, family history of chromosomal rearrangements, or confirmation after abnormal screening tests.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |